Track record
R3i distinguishes between principal investments, transaction mandates, advisory work, portfolio support and historical platform activity.
We do not combine them into a single activity number. Selected evidence is presented according to the role R3i actually performed.
01 · Principal investments
Companies in which an R3i-managed vehicle holds or has held a position, and which may be disclosed publicly. Vehicle, entry date, instrument and current status are stated in diligence materials rather than on this page.
| Company | Domain |
|---|---|
| Asima Health | Human systems |
| Flexpenser | Critical systems |
| Marlee | Strategic technologies |
| Meracle Health | Human systems |
| MGA Thermal | Critical systems |
| Quantum Brilliance | Strategic technologies |
| Soliddd | Human systems |
| StratifiCare | Human systems |
| ViewMind | Human systems |
Inclusion is not a representation of performance, of the size of any position, or of a current holding. Advisory and programme relationships are not presented as holdings. Certain related-party investments exist between R3i-managed vehicles and ventures originated within the platform; these are disclosed to investors and are subject to independent valuation review.
02 · Counterparties
R3i states the nature of each relationship rather than aggregating names for effect.
| Regulated execution | Finalis Securities LLC (SEC File No. 8-70425; CRD No. 305908), member FINRA/SIPC — chaperoning of securities transactions with U.S. persons, and access to its broker-dealer network. |
|---|---|
| Jurisdictions | United States (Delaware) · Luxembourg · Singapore |
| Professional advisers | Legal, audit, fund administration and valuation counterparties are engaged by mandate and disclosed in diligence materials. |
Co-investment, ecosystem and programme relationships are disclosed by name and category in diligence materials, where the relationship type can be stated accurately.
03 · Basis of statement
They do not represent the performance of any single investment vehicle, are not presented net of fees or expenses, and should not be interpreted as indicative of future results. Nothing on this page is an offer of securities or a solicitation of any offer to buy.